CodeineMarket, by Indication (Pain Management, and Cough Management), by Age Group(Adult and Pediatric), by Dosage Form (Tablet, Capsule and Solution/Syrup), byDistribution Channel (Hospital Pharmacies, Retail Pharmacies, and OnlinePharmacies) and by Region (North America, Latin America, Europe, Asia Pacific,Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018– 2026
Codeine is a drug of class knownas opioids, widely used in the treatment and management of mild to moderatepain, severe pain, dry irritating cough, diarrhea, and cold and flu (whencombined with antihistamines and decongestants). Opioids interact with opioidreceptors in the brain and induce effects such as pain relief, relaxation,pleasure, and contentment. Codeine is usually swallowed and comes in differentforms, including tablets, capsules, and solutions/syrups.
Codeine Market Drivers
Codeine is widely used in thetreatment and management of pain and cough. High prevalence of pain due toincreasing ageing population in key regions such as North America, and Asia-Pacific is expected to significantly increase demand for codeine formulationand drive global codeine market growth over the forecast period.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2297
For instance, according to thedata published by National Health Interview Survey (NHIS) in 2016, it wasestimated that around 20.4% (50.0 million) of the adults in the U.S. aresuffering from chronic pain and around 8.0% of adults in the U.S. (19.6 million)had high impact chronic pain.
According to a study published bythe National Centre for Biotechnology Information (NCBI) in 2015, around 19.6%of the individuals aged between 20 to 60 years were suffering from low backpain worldwide.
Codeine Market Regional Analysis
North America codeine market isexpected to hold a dominant position in the global codeine market and toaccount for largest market share over the forecast period, owing to highpresence of key players in the region and approval and launch of novel productsby them in the region.
For instance, in 2015, TrisPharma, Inc. received U.S. Food and Drug Administration approval and launchedits Tuzistra XR (codeine polistirex and chlorpheniramine polistirex),extended-release oral suspension, CIII (DEA Schedule III) in the U.S. market.Tuzistra XR is indicated for the treatment and relief of cough and symptomsassociated with upper respiratory allergies or a common cold in adults aged 18years and older.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/codeine-market-2297
Codeine Market Restraint
Stringent regulations in keyregions for codeine formulation is expected to be a major factor restraininggrowth of the codeine market in the near future. For instance, in February2018, The Therapeutic Goods Administration reclassified codeine as prescriptiononly medicine in Australia, which was previously available as over-the-countermedication. The fact behind this reclassification was that regular use ofmedicines containing codeine may lead to its addiction.
Similarly, Health Canada alsoproposed to ban non-prescription codeine sales in 2017. Reclassification ofcodeine to prescription drugs is expected to hinder its sales and adoption andis expected to restrain the global codeine market growth over the forecastperiod
Codeine Market Key Players
Key players operating in globalcodeine market include: Nexgen Pharma, Inc., Teva Pharmaceutical IndustriesLtd., Wraser Pharmaceuticals LLC, Larken Laboratories, Inc., Aurobindo PharmaLimited, Sun Pharmaceutical Industries Limited, Tris Pharma Inc., and Johnson& Johnson.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2297
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offering action-readysyndicated research reports, custom market analysis, consulting services, andcompetitive analysis through various recommendations related to emerging markettrends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
